Flagship ties up a monster $824M fund to back a new wave of biotech startups seeded in their lab
The venture group that has launched a fleet of new biotechs in recent years, piecing together billions in syndicate cash, has $824 million more to build its next generation of life sciences companies.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
